A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.

DRUG

PD-1 Monoclonal Antibody

Administration by intravenous infusion for a cycle of 3 weeks (Q3W).

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY